Indian Journal of Allergy, Asthma and Immunology

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 35  |  Issue : 1  |  Page : 12--16

Effect of leukotriene receptor antagonist therapy in bronchial asthma – A prospective, preliminary, hospital-based, randomized study in rural Konaseema, Andhra Pradesh


Bhargav Prasad Bathula1, Pandit Vinodh Bandela2, Pentakota Ravikumar3, Bhima Sankar Duvvuri3, Subba Rao Polimati3 
1 Department of Pulmonary Medicine, NRIIMS, Visakhpatnam, Andhra Pradesh, India
2 Department of Biochemistry, Vishnu Dental College, Bhimavaram, Andhra Pradesh, India
3 Department of Pulmonary Medicine, KIMS And RF, Amalapuram, Andhra Pradesh, India

Correspondence Address:
Dr. Bhargav Prasad Bathula
Flat No.104, C Block, Doctor's Quarters, Medical Campus of Anil Neerukonda Hospital, Sangivalasa,Visakhapatnam-531162 Andhra Pradesh
India

BACKGROUND: The role of leukotriene receptor antagonist is well documented in the management of chronic asthma. However, the efficacy in acute asthma is not yet established. AIM AND OBJECTIVES: This study was designed to evaluate the clinical efficacy of oral montelukast as an add-on drug to the standard therapy of the acute attack of bronchial asthma. MATERIALS AND METHODS: A prospective, institutional-based, single-blinded, randomized control study was done. A total of 100 (aged between 18 and 60 years) participants diagnosed with acute exacerbations due to bronchial asthma were enrolled in the study. They were divided into study and control groups randomly. The study group patients were treated with 10 mg of montelukast once in a day for 4 weeks as an add-on drug, whereas the control group received only standard medication of acute bronchial asthma (as per Global Initiative for Asthma guidelines). All the participants were monitored at baseline to every week for a month. RESULTS: All the 100 participants were assessed finally without any dropouts. The baseline characteristics were noted similarly in both groups. The mean age was 35.46 + 13.17 years in the control and 37.86 + 14.43 years in the study group. Majority were males in both the groups. At the end of the 4 weeks of oral montelukast administration, there was improvement in forced expiratory volume in 1 s (FEV1) and peak expiratory flow rate at 2 weeks and 1 month. On many occasions, there was a strong improvement in FEV1 and other clinical parameters after continuous treatment with beta-2 agonists and parenteral corticosteroids for patients with acute asthma. Even though there was no improvement in FEV1/forced vital capacity ratio among both the groups at 2 weeks and 4 weeks, statistically significant improvement was seen between 2 weeks to 1 month on baseline parameters. CONCLUSION: Administration of oral montelukast 10 mg as an add-on drug to standard therapy may help in quick recovery from acute bronchial asthma and relapse.


How to cite this article:
Bathula BP, Bandela PV, Ravikumar P, Duvvuri BS, Polimati SR. Effect of leukotriene receptor antagonist therapy in bronchial asthma – A prospective, preliminary, hospital-based, randomized study in rural Konaseema, Andhra Pradesh.Indian J Allergy Asthma Immunol 2021;35:12-16


How to cite this URL:
Bathula BP, Bandela PV, Ravikumar P, Duvvuri BS, Polimati SR. Effect of leukotriene receptor antagonist therapy in bronchial asthma – A prospective, preliminary, hospital-based, randomized study in rural Konaseema, Andhra Pradesh. Indian J Allergy Asthma Immunol [serial online] 2021 [cited 2022 Jul 5 ];35:12-16
Available from: https://www.ijaai.in/article.asp?issn=0972-6691;year=2021;volume=35;issue=1;spage=12;epage=16;aulast=Bathula;type=0